Hormonal
High BMI acts as a direct risk factor for chronic kidney disease (CKD) through compensatory renal hyperfiltration and increased intraglomerular pressure, independent of diabetes or hypertension.
Maintaining a healthy weight is critical for kidney health. High body weight forces your kidneys to work harder (hyperfiltration), which damages them over time. This damage happens even if you don't have diabetes or high blood pressure. Weight management through lifestyle changes is the primary way to prevent this specific type of kidney injury.
A high BMI is one of the strongest risk factors for new-onset chronic kidney disease... In individuals affected by obesity, a compensatory hyperfiltration occurs to meet the heightened metabolic demands of the increased body weight. The increase in intraglomerular pressure can damage the kidneys and raise the risk of developing chronic kidney disease in the long-term.
Why this rating
Based on numerous population-based studies and meta-analyses cited, though exact causal mechanisms are described as 'unclear'.
Source
Obesity and Kidney Disease: Hidden Consequences of the Epidemic
Csaba P. Kövesdy et al. · Future Science OA · 2017
DOI 10.4155/fsoa-2016-0081
More from this paper
- Weight reduction interventions, including lifestyle changes and ACE inhibition, reduce glomerular hyperfiltration and proteinuria in obese patients with CKD.Good
- Obesity increases the risk of kidney stones (nephrolithiasis) through lower urine pH, increased urinary oxalate, uric acid, and sodium excretion.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →